KELLY DOLLINGER: Open Payments
NPI 1407232978 · CHARLESTON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,657 in 54 payments from 23 companies in 2025. Trend: 2023 $1,171 · 2024 $1,002 · 2025 $2,657
Food & beverage: $1,299Long term medical supply or device loan: $1,180Education: $178
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 18 | $1,346 |
| Kite Pharma, Inc. | 2 | $251 |
| Astellas Pharma US Inc | 2 | $133 |
| Daiichi Sankyo Inc. | 2 | $112 |
| Merck Sharp & Dohme LLC | 4 | $112 |
| Ipsen Biopharmaceuticals, Inc | 2 | $107 |
| Genentech USA, Inc. | 3 | $81 |
| GlaxoSmithKline, LLC. | 3 | $69 |
| PharmaEssentia USA Corporation | 2 | $55 |
| Incyte Corporation | 2 | $51 |
Products named: KISQALI, Yescarta, KEYTRUDA, DATROWAY, SCEMBLIX, BESREMI, Phesgo, BRUKINSA.
Industry payments across SC — which companies pay providers there.
